Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 468

1.

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells.

Cebrià-Costa JP, Pascual-Reguant L, Gonzalez-Perez A, Serra-Bardenys G, Querol J, Cosín M, Verde G, Cigliano RA, Sanseverino W, Segura-Bayona S, Iturbide A, Andreu D, Nuciforo P, Bernado-Morales C, Rodilla V, Arribas J, Yelamos J, de Herreros AG, Stracker TH, Peiró S.

Oncogene. 2019 Aug 28. doi: 10.1038/s41388-019-0969-1. [Epub ahead of print]

PMID:
31462706
2.

Is Spain doing enough to reduce the cardiovascular risk of patients with Human Immnodeficiency Virus infection?

Bernardino JI, Arribas JR.

Rev Clin Esp. 2019 Aug 9. pii: S0014-2565(19)30195-X. doi: 10.1016/j.rce.2019.07.005. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
31405518
3.

Dolutegravir-rilpivirine for virological suppression.

Pozniak AL, Arribas JR.

Lancet HIV. 2019 Sep;6(9):e560-e561. doi: 10.1016/S2352-3018(19)30188-2. Epub 2019 Jul 12. No abstract available.

PMID:
31307947
4.

MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.

Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M.

Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21.

PMID:
31227646
5.

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.

Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.

Cancer Res. 2019 Aug 15;79(16):4258-4270. doi: 10.1158/0008-5472.CAN-18-3835. Epub 2019 Jun 18.

PMID:
31213465
6.

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H.

Lancet HIV. 2019 Jun;6(6):e364-e372. doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5.

PMID:
31068272
7.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M.

AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.

8.

TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.

Díaz-Rodríguez E, Pérez-Peña J, Ríos-Luci C, Arribas J, Ocaña A, Pandiella A.

Cancer Lett. 2019 Jul 1;453:34-44. doi: 10.1016/j.canlet.2019.03.042. Epub 2019 Mar 27.

PMID:
30928382
9.

New filovirus disease classification and nomenclature.

Kuhn JH, Adachi T, Adhikari NKJ, Arribas JR, Bah IE, Bausch DG, Bhadelia N, Borchert M, Brantsæter AB, Brett-Major DM, Burgess TH, Chertow DS, Chute CG, Cieslak TJ, Colebunders R, Crozier I, Davey RT, de Clerck H, Delgado R, Evans L, Fallah M, Fischer WA 2nd, Fletcher TE, Fowler RA, Grünewald T, Hall A, Hewlett A, Hoepelman AIM, Houlihan CF, Ippolito G, Jacob ST, Jacobs M, Jakob R, Jacquerioz FA, Kaiser L, Kalil AC, Kamara RF, Kapetshi J, Klenk HD, Kobinger G, Kortepeter MG, Kraft CS, Kratz T, Bosa HSK, Lado M, Lamontagne F, Lane HC, Lobel L, Lutwama J, Lyon GM 3rd, Massaquoi MBF, Massaquoi TA, Mehta AK, Makuma VM, Murthy S, Musoke TS, Muyembe-Tamfum JJ, Nakyeyune P, Nanclares C, Nanyunja M, Nsio-Mbeta J, O'Dempsey T, Pawęska JT, Peters CJ, Piot P, Rapp C, Renaud B, Ribner B, Sabeti PC, Schieffelin JS, Slenczka W, Soka MJ, Sprecher A, Strong J, Swanepoel R, Uyeki TM, van Herp M, Vetter P, Wohl DA, Wolf T, Wolz A, Wurie AH, Yoti Z.

Nat Rev Microbiol. 2019 May;17(5):261-263. doi: 10.1038/s41579-019-0187-4. No abstract available.

10.

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503.

Gorbatenko A, Søkilde R, Sorensen EE, Newie I, Persson H, Morancho B, Arribas J, Litman T, Rovira C, Pedersen SF.

Sci Rep. 2019 Mar 4;9(1):3352. doi: 10.1038/s41598-019-39733-x.

11.

Clinical and Molecular Comparative Study of Colorectal Cancer Based on Age-of-onset and Tumor Location: Two Main Criteria for Subclassifying Colorectal Cancer.

Álvaro E, Cano JM, García JL, Brandáriz L, Olmedillas-López S, Arriba M, Rueda D, Rodríguez Y, Cañete Á, Arribas J, Inglada-Pérez L, Pérez J, Gómez C, García-Arranz M, García-Olmo D, Goel A, Urioste M, González-Sarmiento R, Perea J.

Int J Mol Sci. 2019 Feb 22;20(4). pii: E968. doi: 10.3390/ijms20040968.

12.

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer.

Blasco-Benito S, Moreno E, Seijo-Vila M, Tundidor I, Andradas C, Caffarel MM, Caro-Villalobos M, Urigüen L, Diez-Alarcia R, Moreno-Bueno G, Hernández L, Manso L, Homar-Ruano P, McCormick PJ, Bibic L, Bernadó-Morales C, Arribas J, Canals M, Casadó V, Canela EI, Guzmán M, Pérez-Gómez E, Sánchez C.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3863-3872. doi: 10.1073/pnas.1815034116. Epub 2019 Feb 7. Erratum in: Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6505.

13.

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial.

Bernardino JI, Mocroft A, Wallet C, de Wit S, Katlama C, Reiss P, Mallon PW, Richert L, Molina JM, Knobel H, Morlat P, Babiker A, Pozniac A, Raffi F, Arribas JR; NEAT001/ANRS143 Trial Study Group.

PLoS One. 2019 Jan 28;14(1):e0209911. doi: 10.1371/journal.pone.0209911. eCollection 2019.

14.

Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study.

Kang SA, Guan JS, Tan HJ, Chu T, Thike AA, Bernadó C, Arribas J, Wong CY, Tan PH, Gudi M, Putti TC, Sohn J, Lim SH, Lee SC, Lim YP.

Clin Cancer Res. 2019 Apr 15;25(8):2588-2600. doi: 10.1158/1078-0432.CCR-18-3228. Epub 2018 Dec 28.

PMID:
30593516
15.

Bleeding Risk Prediction in Patients With Dual Antiplatelet Therapy Undergoing Coronary Artery Bypass Grafting Surgery Using a Rapid Point-of-Care Platelet Function Test.

Tello-Montoliu A, Albaladejo P, Hernández-Romero D, Taboada R, Albacete CL, Arribas JM, Jara R, Veliz A, López-García C, Cánovas S, Valdés M, Rivera-Caravaca JM, Marín F.

Circ Cardiovasc Interv. 2018 Dec;11(12):e007264. doi: 10.1161/CIRCINTERVENTIONS.118.007264. No abstract available.

PMID:
30525983
16.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team.

Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.

PMID:
30420123
17.

TGFβ-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1.

Lambies G, Miceli M, Martínez-Guillamon C, Olivera-Salguero R, Peña R, Frías CP, Calderón I, Atanassov BS, Dent SYR, Arribas J, García de Herreros A, Díaz VM.

Cancer Res. 2019 Jan 1;79(1):33-46. doi: 10.1158/0008-5472.CAN-18-0753. Epub 2018 Oct 19.

PMID:
30341066
18.

p95HER2-T cell bispecific antibody for breast cancer treatment.

Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V, Rubio I, Cortés J, Serra V, Escriva-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, Seoane J, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M, Saura C, Klein C, Arribas J.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaat1445. doi: 10.1126/scitranslmed.aat1445.

PMID:
30282693
19.

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ.

J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21. Erratum in: J Clin Oncol. 2018 Nov 20;36(33):3348. J Clin Oncol. 2019 Feb 1;37(4):362.

20.

Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer.

Méndez O, Peg V, Salvans C, Pujals M, Fernández Y, Abasolo I, Pérez J, Matres A, Valeri M, Gregori J, Villarreal L, Schwartz S Jr, Ramon Y Cajal S, Tabernero J, Cortés J, Arribas J, Villanueva J.

Clin Cancer Res. 2018 Dec 15;24(24):6367-6382. doi: 10.1158/1078-0432.CCR-18-0517. Epub 2018 Aug 22.

PMID:
30135148
21.

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.

Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J.

Oncologist. 2019 May;24(5):680-687. doi: 10.1634/theoncologist.2018-0032. Epub 2018 Aug 20.

PMID:
30126859
22.

Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717.

Perez-Molina JA, Pulido F, Di Giambenedetto S, Ribera E, Moreno S, Zamora J, Coscia C, Alejos B, Pitch J, Gatell JM, De Luca A, Arribas JR.

J Antimicrob Chemother. 2018 Nov 1;73(11):2927-2935. doi: 10.1093/jac/dky299.

PMID:
30085184
23.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.

Thompson JA, Kityo C, Dunn D, Hoppe A, Ndashimye E, Hakim J, Kambugu A, van Oosterhout JJ, Arribas J, Mugyenyi P, Walker AS, Paton NI; Europe–Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team .

Clin Infect Dis. 2019 Mar 19;68(7):1184-1192. doi: 10.1093/cid/ciy589.

24.

Intestinal persistence of a plasmid harbouring the OXA-48 carbapenemase gene after hospital discharge.

Lázaro-Perona F, Ramos JC, Sotillo A, Mingorance J, García-Rodríguez J, Ruiz-Carrascoso G, Paño-Pardo JR, Arribas JR, Herruzo R, Arnalich F.

J Hosp Infect. 2019 Feb;101(2):175-178. doi: 10.1016/j.jhin.2018.07.004. Epub 2018 Jul 11.

PMID:
30017896
25.

PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells.

Georgilis A, Klotz S, Hanley CJ, Herranz N, Weirich B, Morancho B, Leote AC, D'Artista L, Gallage S, Seehawer M, Carroll T, Dharmalingam G, Wee KB, Mellone M, Pombo J, Heide D, Guccione E, Arribas J, Barbosa-Morais NL, Heikenwalder M, Thomas GJ, Zender L, Gil J.

Cancer Cell. 2018 Jul 9;34(1):85-102.e9. doi: 10.1016/j.ccell.2018.06.007.

26.

Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.

Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Alejos B, Schwimmer C, Bernardino JI, Rodes B, Allavena C, Hoffmann C, Gisslén M, de Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR; NEAT 001/ ANRS 143 Study Group.

J Infect Dis. 2018 Oct 5;218(10):1523-1530. doi: 10.1093/infdis/jiy399.

PMID:
29982509
27.

Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease.

Luczkowiak J, Lasala F, Mora-Rillo M, Arribas JR, Delgado R.

J Infect Dis. 2018 Nov 22;218(suppl_5):S574-S581. doi: 10.1093/infdis/jiy302.

28.

Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults.

Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero I, Montes ML, Valencia E, Martín-Carbonero L, Moreno V, González-Garcia J, Rodriguez-Centeno J, Rodes B, Cantos AE, Alejos B, de Miguel R, Arnalich F, Perona R, Arribas JR.

J Infect Dis. 2018 Oct 5;218(10):1531-1540. doi: 10.1093/infdis/jiy364.

PMID:
29912427
29.

Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.

Serrano-Candelas E, Ainsua-Enrich E, Navinés-Ferrer A, Rodrigues P, García-Valverde A, Bazzocco S, Macaya I, Arribas J, Serrano C, Sayós J, Arango D, Martin M.

Mol Oncol. 2018 Aug;12(8):1383-1397. doi: 10.1002/1878-0261.12332. Epub 2018 Jun 30.

30.

Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.

Pérez-Molina JA, Martínez E, Blasco AJ, Arribas JR, Domingo P, Iribarren JA, Knobel H, Lázaro P, López-Aldeguer J, Lozano F, Mariño A, Miró JM, Moreno S, Negredo E, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, von Wichmann MA, Gatell JM.

Enferm Infecc Microbiol Clin. 2019 Mar;37(3):151-159. doi: 10.1016/j.eimc.2018.04.010. Epub 2018 Jun 6. English, Spanish.

PMID:
29884455
31.

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Aug;20(8):990. doi: 10.1038/s41556-018-0052-0.

PMID:
29674681
32.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.

Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.

33.

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0.

Ryom L, Boesecke C, Bracchi M, Ambrosioni J, Pozniak A, Arribas J, Behrens G, Mallon P, Puoti M, Rauch A, Miro JM, Kirk O, Marzolini C, Lundgren JD, Battegay M; EACS Governing Board.

HIV Med. 2018 May;19(5):309-315. doi: 10.1111/hiv.12600. Epub 2018 Mar 1.

34.

Hepatitis C virus core antigen for screening organ donors and recipients.

Benito R, Arribas J, Algarate S, Cebollada R, Gude MJ.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):126-129. doi: 10.1016/j.diagmicrobio.2018.01.021. Epub 2018 Feb 2.

PMID:
29477273
35.

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.

Floros KV, Lochmann TL, Hu B, Monterrubio C, Hughes MT, Wells JD, Morales CB, Ghotra MS, Costa C, Souers AJ, Boikos SA, Leverson JD, Tan M, Serra V, Koblinski JE, Arribas J, Prat A, Paré L, Miller TW, Dozmorov MG, Harada H, Windle BE, Scaltriti M, Faber AC.

Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2594-E2603. doi: 10.1073/pnas.1717820115. Epub 2018 Feb 23.

36.

One-year outcomes after rapid-deployment aortic valve replacement.

Young C, Laufer G, Kocher A, Solinas M, Alamanni F, Polvani G, Podesser BK, Aramendi JI, Arribas J, Bouchot O, Livi U, Massetti M, Terp K, Giot C, Glauber M.

J Thorac Cardiovasc Surg. 2018 Feb;155(2):575-585. doi: 10.1016/j.jtcvs.2017.09.133. Epub 2017 Oct 31.

PMID:
29415382
37.

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Feb;20(2):211-221. doi: 10.1038/s41556-017-0021-z. Epub 2018 Jan 22. Erratum in: Nat Cell Biol. 2018 Apr 19;:.

PMID:
29358704
38.

New Strategies of ARV: the Road to Simplification.

de Miguel Buckley R, Montejano R, Stella-Ascariz N, Arribas JR.

Curr HIV/AIDS Rep. 2018 Feb;15(1):11-19. doi: 10.1007/s11904-018-0371-6. Review.

PMID:
29353398
39.

Incidence and etiological mechanism of stroke in cardiac surgery.

Arribas JM, Garcia E, Jara R, Gutierrez F, Albert L, Bixquert D, García-Puente J, Albacete C, Canovas S, Morales A.

Neurologia. 2017 Dec 14. pii: S0213-4853(17)30349-3. doi: 10.1016/j.nrl.2017.10.004. [Epub ahead of print] English, Spanish.

40.

Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis.

Martín-Pérez R, Yerbes R, Mora-Molina R, Cano-González A, Arribas J, Mazzone M, López-Rivas A, Palacios C.

Oncotarget. 2017 Oct 3;8(55):93688-93703. doi: 10.18632/oncotarget.21458. eCollection 2017 Nov 7.

41.

The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.

Stella-Ascariz N, Arribas JR, Paredes R, Li JZ.

J Infect Dis. 2017 Dec 1;216(suppl_9):S847-S850. doi: 10.1093/infdis/jix430. Review.

42.

A safety evaluation of raltegravir for the treatment of HIV.

de Miguel R, Montejano R, Stella-Ascariz N, Arribas JR.

Expert Opin Drug Saf. 2018 Feb;17(2):217-223. doi: 10.1080/14740338.2018.1411903. Epub 2017 Dec 5. Review.

PMID:
29199485
43.

Persistence and infectivity of Zika virus in semen after returning from endemic areas: Report of 5 cases.

García-Bujalance S, Gutiérrez-Arroyo A, De la Calle F, Díaz-Menéndez M, Arribas JR, García-Rodríguez J, Arsuaga M.

J Clin Virol. 2017 Nov;96:110-115. doi: 10.1016/j.jcv.2017.10.006. Epub 2017 Oct 13.

PMID:
29053990
44.

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.

Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR; DUAL-GESIDA-8014-RIS-EST45 Study Group.

Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. doi: 10.1093/cid/cix734.

PMID:
29020293
45.

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group.

Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6.

PMID:
28993180
46.

Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.

Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA.

J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):102-109. doi: 10.1097/QAI.0000000000001562.

47.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
48.

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.

Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.

49.

Autochthonous Crimean-Congo Hemorrhagic Fever in Spain.

Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M, Astray-Mochales J, Sánchez-Seco MP, Bermejo Lopez E, Menárguez J, Fernández-Cruz A, Sánchez-Artola B, Keough-Delgado E, Ramírez de Arellano E, Lasala F, Milla J, Fraile JL, Ordobás Gavín M, Martinez de la Gándara A, López Perez L, Diaz-Diaz D, López-García MA, Delgado-Jimenez P, Martín-Quirós A, Trigo E, Figueira JC, Manzanares J, Rodriguez-Baena E, Garcia-Comas L, Rodríguez-Fraga O, García-Arenzana N, Fernández-Díaz MV, Cornejo VM, Emmerich P, Schmidt-Chanasit J, Arribas JR; Crimean Congo Hemorrhagic Fever@Madrid Working Group.

N Engl J Med. 2017 Jul 13;377(2):154-161. doi: 10.1056/NEJMoa1615162.

50.

Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.

Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, Nadal-Serrano M, Arribas J, Ocaña A, Pandiella A.

Cancer Res. 2017 Sep 1;77(17):4639-4651. doi: 10.1158/0008-5472.CAN-16-3127. Epub 2017 Jul 7.

Supplemental Content

Loading ...
Support Center